Health Checkup (II) | Understanding Your Gynecologic Cancer Dual-Screening Report in Three Simple Steps
After completing the "gynecologic dual screening" examination—endometrial cancer (CISENDO®: CDO1/CELF4) and cervical cancer (CISCER®: PAX1/JAM3) methylation detection—understanding your report is the first step in health management. Please remember: this is a "health risk advisory," designed to guide your future health management direction, not a definitive diagnosis.
In Checkup Series (1): Safeguarding Women's Health—Starting with One Gynecologic Dual Screening, Adding Double Assurance to Your Checkup, we explained how our gynecologic dual screening can add a double layer of protection to your health checkup.
Your endometrial cancer (CISENDO®: CDO1/CELF4) and cervical cancer (CISCER®: PAX1/JAM3) methylation detection report typically shows one of three scenarios, each with clear action guidelines:
Scenario 1: Both Negative (Both indicators show low risk)
- What the report says: Current testing indicates that your risk of high-grade cervical and endometrial lesions (cancer) is relatively low.
- What you should do: This is a reassuring genetic risk result. Please maintain a healthy lifestyle and follow up with regular checkups as advised by your doctor. Note: Even with both negative results, if you have HPV infection, abnormal symptoms (such as abnormal bleeding), or other gynecologic conditions, you should still seek medical attention—this is separate from cancer screening.
Scenario 2: Single Positive (One indicator shows high risk)
-
What the report says: This indicates that either your cervical or endometrial area requires further attention.
-
What you should do:
-
If the report shows "cervical cancer high risk (PAX1/JAM3 positive)": Please schedule an appointment with gynecology or a cervical clinic. The doctor will consider your HPV history, TCT (cytology) results, symptoms, and other factors to make a comprehensive assessment, and may recommend colposcopy for clearer evaluation of cervical status. During your visit, you may remind the doctor to examine occult areas such as the cervical canal. If no lesions requiring immediate invasive treatment are found, you can discuss fertility or other personal considerations with the doctor to determine a minimally invasive (laser, etc.) treatment plan and/or regular follow-up (3–6 months) protocol.
-
If the report shows "endometrial cancer high risk (CDO1/CELF4 positive)": Please schedule a gynecology appointment. The doctor will typically first arrange a transvaginal ultrasound to assess the endometrium, then combine your symptoms, family history, and other risk factors to determine whether hysteroscopic examination or a regular follow-up plan (3–6 months) is needed.
-
Why regular follow-up: Because methylation is an early risk indicator. If hospital examination does not currently reveal lesions requiring immediate treatment, this is precisely an important health warning—reminding you to adjust your lifestyle, pay closer attention to your health, and follow medical advice for regular methylation follow-up (3–6 months) and other necessary examinations.
-
Scenario 3: Both Positive (Both PAX1/JAM3 and CDO1/CELF4 show high risk)
-
What the report says: This indicates that both your cervical and endometrial areas require close attention. Due to their anatomical proximity, both may need separate evaluation.
-
What you should do: Please bring your report and visit a hospital gynecology department. The doctor will systematically arrange examinations (potentially investigating from cervix to endometrium individually), clarifying the status of each site, and develop a subsequent treatment and/or regular follow-up (3–6 months) plan.
-
Why regular follow-up: Because methylation is an early risk indicator. If hospital examination does not currently reveal lesions requiring immediate treatment, this is precisely an important health warning—reminding you to adjust your lifestyle, pay closer attention to your health, and follow medical advice for regular methylation follow-up and other necessary examinations.
Core Advice
Regardless of the results, please remain calm and positive. The purpose of screening is precisely "early detection, early intervention." A positive result means that the screening has served its critical warning function—guiding you to take action at the earliest stage of a problem. This is the best time to care for yourself and proactively manage your health. Please be sure to consult a qualified physician for the most appropriate guidance tailored to your individual situation.
Start with one efficient, cutting-edge screening—take charge of your health and embrace the future with confidence.
Beijing Origin-Poly Co., Ltd. is a technology enterprise driven by innovation and committed to health. As a pioneer in the field of early diagnosis of gynecologic tumors, CISPOLY has developed early detection products for cervical cancer, endometrial cancer, ovarian cancer and other gynecologic malignancies based on proprietary technologies and patent-protected biomarkers, filling gaps in this field.
As women's awareness of their own health continues to grow, the women's health market holds tremendous potential. Beyond the gynecologic tumor early screening and diagnosis product line, CISPOLY will continue to establish additional women's health-related product pipelines, striving to become a technology innovation leader in the women's health market.